Abstracts tagged "juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis-enthesitis (ERA)"

Abstract Number: 371 • ACR/ARHP Annual Meeting 2017
Longer Term Outcomes of Chronic Relapsing Multifocal Osteomyelitis in a UK Tertiary Adolescent and Young Adult Rheumatology Centre
Kristina E.N. Clark¹, Francesca Josephs², Nicola Daly³, Claire Louise Murphy³ and Debajit Sen⁴, ¹Rheumatology, University college London Hospitals, London, United Kingdom, ²rhuematology, UCL, London, United Kingdom, ³Rheumatology, University College London Hospital, London, United Kingdom, ⁴Adolescent Rheumatology Department, University College London Hospital NHS Trust, London, United Kingdom
Background/Purpose: Chronic relapsing multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone condition presenting primarily in children & adolescents. It characteristically affects the epiphysis & metaphysis…
Abstract Number: 2431 • ACR/ARHP Annual Meeting 2015
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Daniel Lovell¹, Nicolino Ruperto², Daniel J. Kingsbury¹, Rubén Burgos-Vargas², Tomoyuki Imagawa³, G Horneff², Pierre Quartier⁴, Steven Goodman¹, Andreas Reiff¹, Edward H. Giannini¹, Anabela Cardoso⁵, Jaclyn K. Anderson⁶, Nupun A. Varothai⁶, Jasmina Kalabic⁶ and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genova, Italy, ³Kanagawa Children’s Medical Center, Yokohama City, Japan, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie, Amadora, Portugal, ⁶AbbVie, North Chicago, IL
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…
Abstract Number: 2790 • ACR/ARHP Annual Meeting 2013
The Research In Arthritis In Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Are We Achieving Clinically Important Outcomes?
Deborah M. Levy¹, Shirley ML Tse¹, Elizabeth Stringer², Jaime Guzman³, Roberta A. Berard⁴, Karen Watanabe Duffy⁵, Dax Rumsey¹, Mercedes O. Chan³, Rosie Scuccimarri⁶, Adam M. Huber⁷, Lori B. Tucker³, Rae SM Yeung¹, Ciaran M. Duffy⁵, Kiem Oen⁸ and The ReACCh Out Investigators⁹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ³Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ⁹The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Recent data suggests that achievement of inactive disease and early disease remission may result in improved outcomes for patients with juvenile idiopathic arthritis (JIA). …